OBJECTIVE: To observe therapeutic efficacy and safety of hyperthermia combined with pemetrexed and cisplatin for medium and advanced lung adenocarcinoma. METHODS： Medical information of 120 patients with medium and advanced lung adenocarcinoma were analyzed retrospectively. They were divided into control group （60 cases） and observation group （60 cases） according to therapy method. Control group was given Pemetrexed disodium for injection 500 mg/m2 intravenously， d1+Cisplatin for injection 75 mg/m2 intravenously， d2-4. A treatment course lasted for 21 d， and both received 2 courses of treatment at least. Observation group was additionally given hyperthermia， once a month， 2-4 times in total， on the basis of control group. Clinical efficacies， the improvement of life quality and the occurrence of toxic reaction were observed in 2 groups. RESULTS： Both groups received 2 courses of treatment at least. Total response rate of observation group （63.3％） was significantly higher than that of control group （36.7％）， and the improvement rate of life quality （60.0％） was significantly higher than control group （33.3％）， with statistical significance （P＜0.05）. There was no statistical significance in Ⅲ-Ⅳ degree liver and renal function injury， myelosuppression or the incidence of gastrointestinal tract between 2 groups （P＞0.05）. CONCLUSIONS: Hyperthermia combined with pemetrexed and cisplatin shows significant therapeutic efficacy for medium and advanced lung adenocarcinoma and improves survival quality without increasing the occurrence of toxic reaction.